Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | TERT | O14746 | 5/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555856 | 1.00 | GSR (0.43) | GSRDPP7DPP9DPP8TERT | |
| Lysine SCHEMBL28207112 | 0.70 | GSR (0.67) | GSRDPP7DPP9DPP8MMP2 | |
| Lysine SCHEMBL3868637 | 0.70 | GSR (0.67) | GSRDPP7DPP9DPP8MMP2 | |
| SCHEMBL30341824 | 0.67 | GSR (0.52) | GSRDPP7DPP9DPP8TERT | |
| SCHEMBL28992842 | 0.66 | GSR (0.55) | GSRDPP7DPP9DPP8TERT | |
| SCHEMBL9631019 | 0.66 | GSR (0.55) | GSRDPP7DPP9DPP8TERT | |
| SCHEMBL9315967 | 0.65 | GSR (0.48) | GSRDPP7DPP9DPP8MMP2 | |
| SCHEMBL555855 | 0.65 | DPP7 (0.51) | GSRDPP7DPP9DPP8DPP4 | |
| Lysine SCHEMBL29075874 | 0.65 | GSR (0.95) | GSR | |
| SCHEMBL6022461 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398498-B1 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 | UCB BIOPHARMA SPRL (BE) | 2018-09-05 | — | — | EP | claimed |
| EP-3339325-A1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | UCB Biopharma SPRL (BE) | 2018-06-27 | — | — | EP | claimed |
| US-9957328-B2 | Bacterial host strain expressing recombinant DSBC | UCB PHARMA, S.A. (GB) | 2018-05-01 | — | — | US | claimed |
| US-20170335003-A1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | CELLTECH R&D LTD. (GB) | 2017-11-23 | — | — | US | claimed |
| EP-2731973-B1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | UCB BIOPHARMA SPRL (BE) | 2017-11-15 | — | — | EP | claimed |
| US-9725516-B2 | Bacterial host strain expressing recombinant DSBC | UCB PHARMA, S.A. (BE) | 2017-08-08 | — | — | US | claimed |
| US-20140141468-A1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | UCB PHARMA, S.A. (BE) | 2014-05-22 | — | — | US | claimed |
| EP-2731973-A1 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC | UCB Pharma, S.A. (BE) | 2014-05-21 | — | — | EP | claimed |
| US-8614295-B2 | Antibody molecules having specificity for human OX40 | UCB PHARMA S.A. (BE) | 2013-12-24 | — | — | US | claimed |
| US-20130330344-A1 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 | UCB PHARMA S.A. (BE) | 2013-12-12 | — | — | US | claimed |
| US-20050181448-A1 | Biological products | UCB S.A. (BE) | 2005-08-18 | — | — | US | claimed |
| CN-1568331-A | Biological products | CELLTECH R&D LTD (GB) | 2005-01-19 | — | — | CN | claimed |
| WO-2004072116-A2 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-1β | CELLTECH R & D LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| EP-1438340-A2 | ANTIBODIES AGAINST KDR, THEIR PRODUCTION AND USES | Celltech R & D Limited (GB) | 2004-07-21 | — | — | EP | claimed |
| US-20030157061-A1 | Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | US | claimed |
| WO-2003031475-A2 | ANTIBODIES AGAINST KDR, THEIR PRODUCTION AND USES | CELLTECH R & D LIMITED (GB) | 2003-04-17 | — | — | WO | claimed |
| EP-1287140-A1 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN TUMOR NECROSIS FACTOR ALPHA, AND USE THEREOF | Celltech R&D Limited (GB) | 2003-03-05 | — | — | EP | claimed |
| US-20030026805-A1 | Biological products | UCB S.A. (BE) | 2003-02-06 | — | — | US | claimed |
| US-20020151682-A1 | Biological products | UCB S.A. (BE) | 2002-10-17 | — | — | US | claimed |
| WO-2001094585-A1 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN TUMOR NECROSIS FACTOR ALPHA, AND USE THEREOF | CELLTECH R & D LIMITED (GB) | 2001-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130330344-A1 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 | LY96, IGSF11, FCGR1A | GSR 4729/4885DPP7 4445/4885DPP9 4018/4885 |
| US-20030157061-A1 | Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor | TNF, TNFRSF1A, CD40 | GSR 759/4885DPP7 1077/4885DPP9 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.